MarketWendy Chung
Company Profile

Wendy Chung

Wendy K. Chung is an American clinical and molecular geneticist and physician. She is the Chair of the Department of Pediatrics at Boston Children's Hospital and is on the faculty at Harvard Medical School. She is the author of 700 peer-reviewed articles and 75 chapters and has won several awards as a physician, researcher, and professor. Chung helped to initiate a new form of newborn screening for spinal muscular atrophy which is used nationally and was among the plaintiffs in the Supreme Court case which banned gene patenting.

Early life and education
Chung was born in Nebraska and raised in southern Florida. Her parents were involved in science and medicine: her father was an organic chemistry professor and her mother worked in a medical laboratory. Chung earned a bachelor's degree in biochemistry and economics at Cornell University, graduating in 1990. She was a graduate student of Dr. Rudy Leibel at Rockefeller, who described her as a "triple threat" due to her capability as an "equally gifted scientist, clinician, and teacher." Chung also completed an internship, residency, and fellowship at the New York-Presbyterian Hospital, Columbia University Medical Center. Both her internship and residency were focused in pediatrics, while her two fellowships were focused in Molecular Genetics and Clinical Genetics. == Career ==
Career
Chung was the Kennedy Family Professor of Pediatrics at Columbia University and directed the Pediatric Neuromuscular Network Molecular Core, the New York Obesity Center Molecular Genetics Core and the Diabetes and Endocrine Research Center Molecular Genetics Core, among her positions. Supreme Court Case Involvement Chung was an original plaintiff in the Supreme Court case which overturned that ability to patent genes, Association for Molecular Pathology v. Myriad Genetics, Inc. Chung became a plaintiff with the ACLU after approaching both the NIH and Congress as she believed that the patenting of genes restricted access and quality of care the patients are eligible to receive. The court sided with the Association for Molecular Pathology unanimously, and determined that as genes are natural, they are not able to be patented. Chung believes that these decisions will allow patients to receive all the information resulting from genome sequencing, and allowing testing for specific diseases – such as the test for breast cancer – thus enabling patients to know more about their own health. She directs the GUARDIAN newborn screening program. Simons Foundation Chung directed clinical research at the Simons Foundation Autism Research Initiative. She leads both the Simons Foundation Powering Research through Knowledge (SPARK); which is seeking to create a large group of individuals with autism who contribute data in the form of genetic, medical, and behavioral information, and Simons Searchlight (previously known Simons Variation in Individuals Project) in which individuals with a variant in a specific segment of their genetic makeup increases their probability of autism are studied through various assessments and neuroimaging to identify new profiles which may be shared by these individuals. In these endeavors, Chung works to manage research programs, evaluate new treatments and medications, and develop novel outcome measures for evaluation of the new treatments. Furthermore, she seeks to identify gene associations with autism and the specific clinical features which may characterize particular gene associations. Alongside her research endeavors, Chung works with the families involved in the project to create community and help them to understand autism and its causes more completely. == Research contributions ==
Research contributions
Throughout her career, Chung's research has largely focused on the genetic basis of human diseases, specifically learning the discovery of new genes and mutations associated with diseases, then implementing these revelations into clinical treatments. Obesity and diabetes Chung worked primarily in research related to the influence of genetic variation in susceptibility to obesity and diabetes, using rodent genetic models as a foundation from which to expand research to humans. In this research, Chung was able to clone a rodent gene (leptin receptor) leading to obesity and regulation of body weight.), atresia (through project CARE) and congenital heart disease. ALYREF and MYRF in causing CDH. Her studies on congenital heart disease have been published in the journals Nature and Science, and have shown that mutations in many different genes are a cause of congenital anomalies and can also be associated with neurodevelopmental disorders. Chung discussed different ways in which genetics and autism interact, with some individuals with autism resulting from a single genetic factor, and other individuals with multifactorial autism, caused by multiple factors and genes. Additionally, Chung touched on the ameliorable effects of early detection of autism, along with new testing practices such as eye tracking test for babies which detects whether they have difficulty maintaining eye contact. Additionally, Chung was featured in part one of a Ken Burns documentary called The Gene: An Intimate History, which focuses on the efforts of Luke Rosen and Sally Jackson, the founders of KIF1A.org, and researchers to find a treatment for KAND patients. Chung has also started a treatment program using an ASO to treat KAND and has a patient in an N of 1 trial to determine efficacy of this strategy. Papers == Recognition and awards==
Recognition and awards
2021 American Association of Physicians 2020 National Academy of Medicine 2019 Rare Impact Award, National Organization of Rare Diseases == Personal life ==
Personal life
She has two sons and spends most of her free time with her family, engaging in hiking, swimming, biking, solving puzzles, and going on scavenger hunts. == References ==
tickerdossier.comtickerdossier.substack.com